Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in variable
bleeding symptoms and thrombocytopenia. In the last decade, changes in our …

Immune thrombocytopenia (ITP) is an autoimmune process resulting in increased
destruction and inadequate production of platelets that can result in bleeding, fatigue, and …

Anti CD-19 chimeric antigen receptor T (CAR-T) cells demonstrate effective early anti-tumor
response; however, impaired hematopoietic recovery is observed in about 30% of patients …

Immune thrombocytopenic purpura (ITP) is an autoimmune condition that affects nearly 1:
10,000 people in the world. It is traditionally defined by a platelet count of less than 100 x 10 …

Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in
clinical practice. The International Working Group (IWG) on ITP has published several …

Persistent immune thrombocytopenia (ITP) patients require second‐line treatments, for
which information on clinical outcomes are lacking. A systematic review and network meta …

In 2012, ITP group of Blood Coagulation Abnormalities Research Team with funding from
the Ministry of Health, Labour and Welfare Research Grant for Overcoming Intractable …

Immune thrombocytopenia (ITP) is an autoimmune disorder that induces a decrease in the
number of circulating platelets due to spleen destruction and inability of megakaryocytes to …

The treatment goal for patients with immune thrombocytopaenia (ITP) is to raise platelet
counts to levels that minimize or stop bleeding. Thrombopoietin receptor agonists (TPO …

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder presenting with low
platelet count< 100× 109/L. The condition affects both adults and children. Thrombopoietin …